Literature DB >> 2868869

The effects of cyclosporin A (CsA) on hepatic microsomal drug metabolism in the rat.

J A Augustine, M A Zemaitis.   

Abstract

The effects of cyclosporin A (CsA), a powerful immunosuppressant, on the hepatic microsomal mixed function oxidase (MFO) system was studied in male rats. Difference spectroscopy studies indicated that CsA binds to cytochrome P-450 producing a type I spectral change. To investigate potential interactions with the MFO system, CsA was administered orally at doses of either 25 mg/kg or 50 mg/kg once daily for 9 days. Various metabolic parameters were examined, including: levels of microsomal protein, cytochrome P-450, and cytochrome b5, NADPH-cytochrome c reductase activity, N-demethylation of ethylmorphine (ETM), and p-hydroxylation of aniline (ANL). Rats treated with 50 mg/kg showed a 25% or greater decrease over controls in all parameters examined except microsomal protein and cytochrome b5 levels. Rats treated with 25 mg/kg showed a 28% or greater decrease in all parameters except microsomal protein, cytochrome b5, and cytochrome P-450. Kinetic studies of ETM-N-demethylase and ANL-hydroxylase activities were conducted either with microsomes prepared from CsA-treated animals (50 mg/kg/day for 5 days) or with pooled microsomes prepared from untreated animals to which CsA was added directly. Enzyme reaction velocities were measured and apparent KM and apparent Vmax were determined. Studies with CsA-treated animals revealed a 57% decrease in both KM and Vmax for ETM-N-demethylase, and a 46% decrease in KM and a 32% decrease in Vmax for ANL-hydroxylase. Studies involving direct addition of CsA to microsomes at final concentrations of 0.01 mM and 0.10 mM revealed no significant changes in apparent KM or Vmax for either enzyme.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868869

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Effect of Chronic Therapy on Absorption and Disposition of Cyclosporine.

Authors:  K Habucky; R Venkataramanan; R J Ptachcinski; G J Burckart; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

2.  Biopharmaceutical aspects of FK-506.

Authors:  R Venkataramanan; V S Warty; M A Zemaitis; A T Sanghvi; G J Burckart; H Seltman; S Todo; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

3.  Is cyclosporin A an inhibitor of drug metabolism?

Authors:  G Li; G Treiber; J Meinshausen; J Wolf; J Werringloer; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

4.  Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450.

Authors:  Alexandra Krauskopf; Timo M Buetler; Nathalie S D Nguyen; Katherine Macé; Urs T Ruegg
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis.

Authors:  H M Princen; P Meijer; B G Wolthers; R J Vonk; F Kuipers
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

6.  Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibition.

Authors:  F Serino; J Grevel; K L Napoli; B D Kahan; H W Strobel
Journal:  Mol Cell Biochem       Date:  1993-05-26       Impact factor: 3.396

7.  Importance of endogenous prostaglandins for the toxicity of cyclosporin A to rat endocrine and exocrine pancreas?

Authors:  M Rünzi; B M Peskar; J von Schönfeld; M K Müller
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

8.  The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.

Authors:  T L Schwinghammer; D Przepiorka; R Venkataramanan; C P Wang; G J Burckart; C S Rosenfeld; R K Shadduck
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

9.  Interactions between cyclosporin A, indomethacin and 16,16-dimethyl prostaglandin E2: effects on renal, hepatic and gastrointestinal toxicity in the rat.

Authors:  P H Whiting; N Barnard; A Neilsch; J G Simpson; M D Burke
Journal:  Br J Exp Pathol       Date:  1987-12

Review 10.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.